

AMENDMENT

In the Specification

At page 2, after line 25, please insert the following:

--Brief Description of the Drawings

A¹ Figure 1 is a graph showing estimated plasma concentration of desglymidodrine over time.

Figure 2 is a graph showing the release rate of desglymidodrine over time from a solid oral dosage form according to one aspect of the invention.

Figure 3 is a graph showing the release rate of midodrine from various formulations.

Figure 4 is a graph showing the release rate of desglymidodrine from various formulations.

Please delete the abstract on page 116 and insert therefore:

--Abstract

A² The invention provides solid oral dosage forms of desglymidodrine. In one aspect, a controlled release composition is provided which is designed to release desglymidodrine after oral intake in a manner which enables absorption to take place in the gastrointestinal tract so that a relatively fast peak plasma concentration, followed by a prolonged and relatively constant plasma concentration of desglymidodrine. The invention also provides a method for treating orthostatic hypotension and/or urinary incontinence, the method comprising administration to a